Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
1 "Remdesivir"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea
Mi Yu, Bryan Inho Kim, Jungyeon Kim, Jin Gwack
Osong Public Health Res Perspect. 2022;13(5):370-376.   Published online October 18, 2022
DOI: https://doi.org/10.24171/j.phrp.2022.0138
  • 1,959 View
  • 69 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDF
Objectives
This study analyzed the clinical outcomes of remdesivir treatment in coronavirus disease 2019 (COVID-19) patients in South Korea.
Methods
This retrospective cohort study involved the secondary analysis of epidemiological data. Among patients diagnosed with COVID-19 from July 2, 2020 to March 23, 2021 (12 AM), 4,868 who received oxygen therapy and were released from isolation after receiving remdesivir treatment were assigned to the treatment group, and 6,068 patients who received oxygen therapy but not remdesivir were assigned to the untreated group. The study subjects included children under the age of 19. The general characteristics and severity were compared between the groups. Differences in the time to death and mortality were also compared.
Results
In the untreated group, the hazard ratio [HR] for mortality was 1.59 among patients aged ≥70 years and 2.32 in patients with severe disease in comparison to the treatment group. In a comparison of survival time among patients with severe disease aged ≥70 years, the HR for mortality before 50 days was 2.09 in the untreated group compared to the treatment group.
Conclusion
Patients with remdesivir treatment showed better clinical outcomes in this study, but these results should be interpreted with caution since this study was not a fully controlled clinical trial.

Citations

Citations to this article as recorded by  
  • The Role of Multidimensional Prognostic Index to Identify Hospitalized Older Adults with COVID-19 Who Can Benefit from Remdesivir Treatment: An Observational, Prospective, Multicenter Study
    Carlo Custodero, Nicola Veronese, Eva Topinkova, Helena Michalkova, Maria Cristina Polidori, Alberto Cella, Alfonso J. Cruz-Jentoft, Christine A. F. von Arnim, Margherita Azzini, Heidi Gruner, Alberto Castagna, Giovanni Cenderello, Romina Custureri, Tania
    Drugs & Aging.2023; 40(7): 643.     CrossRef
  • Remdesivir: A Review in COVID-19
    Hannah A. Blair
    Drugs.2023; 83(13): 1215.     CrossRef

PHRP : Osong Public Health and Research Perspectives